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ABSTRACT
Most studies of tumor instability are PCR-based.
PCR-based methods may underestimate mutation
frequencies of heterogeneous tumor genomes.
Using a novel PCR-free random cloning/sequencing
method, we analyzed 100kb of total genomic DNA
from blood lymphocytes, normal prostate and tumor
prostate taken from six individuals. Variations
were identified by comparison of the sequence of
the cloned fragments with the nr-database in
Genbank. After excluding known polymorphisms
(by comparison to the NCBI dbSNP), we report a
significant over-representation of variants in the
tumors: 0.66 variations per kilobase of sequence,
compared with the corresponding normal prostates
(0.14 variations/kb) or blood (0.09 variations/kb).
Extrapolating the observed difference between
tumor and normal prostate DNA, we estimate
1.8million somatic (de novo) alterations per tumor
cell genome, a much higher frequency than
previous measurements obtained by mostly PCR-
based methods in other tumor types. Moreover,
unlike the normal prostate and blood, most of the
tumor variations occur in a specific motif (P=0.046),
suggesting common etiology. We further report high
tumor cell-to-cell heterogeneity. These data have
important implications for selecting appropriate
technologies for cancer genome projects as well
as for understanding prostate cancer progression.
INTRODUCTION
Prostate cancer is the most common malignancy in men,
with over 300000 diagnoses and 30000 deaths in the
United States alone (1). Underlying factors implicated in
disease etiology include diet, ethnicity, genetic predisposi-
tion, hormones and other environmental contributors (2).
Most experts agree that genomic instability plays a
role during cancer evolution, but its exact signiﬁcance
is debated (3). Two types of genomic instability are
evident in most cancers (3): large-scale alterations (e.g.
aneuploidy, translocations) and small-scale alterations
(e.g. single nucleotide substitutions, microsatellite instabil-
ity). The extent of small-scale somatic alterations has been
mostly probed with PCR-based methods: the majority
of tumors display low frequencies of genomic instability
(4–6) although a screen of the complete protein kinase
gene family (which contains genes that are commonly
mutated in tumors) revealed the equivalent of 142000
alterations per tumor cell (7). PCR-based methods
however are bound to underestimate the total number of
variations present in heterogeneous genomes because they
only record the most common genotypes in a pool of het-
erogeneous molecules (8). In order to account for tumor
heterogeneity one needs to employ cell-speciﬁc or single
molecule analyses, such as sequencing individual clones.
Single molecule PCR analysis has resulted in the discov-
ery of signiﬁcant instability in various types of tumors (9),
but the target sequence analyzed is a 4-bp fragment in a
p53 intron, making it diﬃcult to extrapolate those
mutation frequencies for the whole cancer genome.
Single molecule methods based on next generation
sequencing have identiﬁed somatic tumor mutations not
detected by Sanger sequencing (10), but the cost per
sequencing run is signiﬁcant, and the relatively high back-
ground makes it impossible to identify mutations present
in <0.2% of the tumor genome (10). Furthermore, both of
the above methods are based on the presumed reduction
of heterogeneous tumor samples to single molecules by
dilution (before ampliﬁcation). It is technically much
harder to guarantee generation of single DNA molecules
by dilution, compared to, e.g. cloning. Accurate measure-
ment of the extent of genomic instability in tumors is
important for understanding cancer etiology, disease
prognosis and for successful treatment.
We recently reported a high frequency of somatic
mutations in several genes in prostate cancer tissue, and
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(THEMIS) in the mutation sites (11). The THEMIS
motif {WKVnRRRnVWK: W=A/T, K=G/T, V=G/
A/C, R=purine (A/G); n =any nucleotide; total number
of n=0–2 nucleotides; the underline indicates the position
of the mutated base}, was found signiﬁcantly more often
than expected at the somatic mutation sites of both
prostate and breast cancer tissue, when one mismatched
was allowed (11). Here we utilize a PCR-free cloning/
sequencing approach to report much higher somatic
mutation frequencies than previously measured in cancer
tissue, mostly from intergenic regions across the tumor
genome.
MATERIALS AND METHODS
Samples
Prostatic adenocarcinoma patients used for the assessment
of variation frequencies were of African American or
Hispanic American background and were obtained from
the Multiethnic Cohort (12). Patient age at diagnosis
varied from 55 to 66 years and grading (Gleason score)
varied from 6 to 7. One of the patients refused to provide
blood DNA. For the assessment of heterogeneity we used
Caucasian prostatic adenocarcinoma patients taken from
a diﬀerent dataset (13). Patient age at diagnosis varied
from 56- to 72-years old and stage varied from pT2a
to pT3c (using the TNM staging system (14).
DNA isolation
Prostate tissue and blood were collected from each
patient. Prostate tissue was microdissected manually.
DNA was extracted from the prostate as in ref. (13) and
from the blood with standard methods (15).
Shotgun cloning and sequencing
A 100–250ng genomic DNA from matched lymphocytes,
normal prostate and prostate tumor were digested with
AluI (NEB, Beverly, MA, USA) and ligated into (SmaI)
linearized, dephosphorylated pUC18. The plasmids were
transformed into One Shot TOP10 Ultracompetent
Escherichia coli cells (Invitrogen, Carlsbad, CA, USA)
and recombinants were identiﬁed via blue-white screening.
Plasmids were spin-column prepared (Qiagen, Valencia,
CA, USA) and DNA sequenced (Applied Biosystems
BigDye v3.1, Foster City, CA, USA) using M13F or
M13R universal primers (IDT, Coralville, IA, USA).
Sequencing reactions were aliquoted in 0.2% SDS,
heated to 98C for 5min, prior to puriﬁcation by
AutoSeq50 size exclusion chromatography (Amersham
Biosciences, Pittsburg, PA, USA). Puriﬁed samples were
then run on an ABI 3100 automated DNA sequencer.
Genomic heterogeneity assessment
A 50–100ng of matched prostate tumor and blood
DNAs were PCR ampliﬁed on a Robocycler thermal
cycler (Stratagene, La Jolla, CA) using 2.5U AmpliTaq
Gold DNA polymerase (Roche), 1.5mM MgCl2, 0.5mM
(CA)8RY oligo and 5% v/v DMSO, using the following
PCR protocol: 15min at 95C for 1cycle, followed by
40cycles of 2min 20s at 95C, 1min 20s at 48C and
2min 20s at 72C. PCR products were AluI-digested
and then shotgun cloned and sequenced as described
above.
Variant identiﬁcation
We sequenced 60–100 clones from each blood, tumor and
normal prostate sample, bi-directionally. Vector sequences
were removed, and each clone pair (forward and reverse
sequence) was aligned using BLAST 2 SEQUENCES
(www.ncbi.nlm.nih.gov/BLAST/). Mismatches were
manually edited based on the sequence information from
both strands (to remove obvious base-calling errors).
This ﬁnal edited sequence output was then compared
to the nr-database in Genbank using BLASTN (www.
ncbi.nlm.nih.gov/BLAST/). Variations with the best
match were conﬁrmed by blasting against the genomic
reference sequence. Conﬁrmed variations were scored,
unless they represented >5% of the total sequence, in
which case the clone was rejected from the analysis (for
further explanation see the Discussion section).
All conﬁrmed variations were blasted against dbSNP
build 129 (http://www.ncbi.nlm.nih.gov/SNP/snp_blast
ByOrg.cgi), to identify known polymorphisms.
Statistics
Variation frequency. All statistical analyses comparing
variation frequency for the three groups (blood, normal
prostate and prostate tumor) were performed using
SAS statistical software, version 9.1 (SAS Institute,
Cary, NC, USA), and all results were tested at a 5%
level of signiﬁcance. Data were summarized using descrip-
tive statistics such as mean and standard deviations.
The analysis of variance (ANOVA) method and
Bonferroni multiple comparison test as a post hoc
analysis were used for comparing means for these three
frequency groups.
THEMIS motif. Two-sided P-values were calculated for
the prostate tumor and blood/normal prostate groups
using the chi-squared test.
RESULTS
We measured the frequency of small-scale somatic
alterations in sporadic prostate cancer by using a PCR-
free cloning and sequencing method (Supplementary
Figure S1). This technique was used to identify the
number of variants present in randomly cloned genomic
pieces of prostate tumor, normal prostate and blood
DNAs from the same individual by ﬁrst sequencing
each DNA fragment and then comparing the sequence
to the nr (nonredundant)- and refseq_genomic-databases
in Genbank (Supplementary Figure S1). Our prostate
tumor DNA samples were obtained by microdissecting
formalin ﬁxed tissue slides under the microscope, a tech-
nique that results in minimum normal DNA contamina-
tion of the tumor material, but which may cause
an artiﬁcial increase of the mutation frequencies (18).
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analyzed formalin ﬁxed normal tissue from the same
slides, in addition to non-ﬁxed blood DNA from the
same patients. We purposely chose to analyze relatively
advanced prostate tumors (Gleason score 6–7), reasoning
that failure to identify an increased alteration frequency
by this point in tumor evolution may indicate that
genomic instability does not play a major role in
prostate cancer progression.
After sequencing 100kb of total DNA from blood
lymphocytes, normal prostates and tumor prostates
taken from six men with prostate cancer, we identiﬁed
46 variations in the tumors, 30 in the normal prostates
and 26 in the blood DNAs. Each of these variations was
conﬁrmed in independent sequencing reactions using both
forward and reverse primers. Excluding variations found
in dbSNP build 129 (www.ncbi.nlm.nih.gov/SNP/;
presumed to be polymorphisms) resulted in 20 variations
remaining in the tumors, 5 in normal prostates and 4
in the blood DNA. The only statistically signiﬁcant
diﬀerences were between the mean tumor and normal
prostate DNA variation frequency, and the mean tumor
and blood DNA variation frequency (Figure 1A; see
‘Materials and Methods’ section). Although our analysis
is based on distinct sequences from each sample type
(normal prostate, tumor and blood), the randomness
of the cloning methodology and of the analyzed data
(evidenced by e.g. G/C content and chromosomal distri-
bution; Supplementary Figure S2) makes it possible to
measure variation frequencies across each type of
genome. Subtracting genomic variation frequencies
between tumor and normal prostate can thus estimate
the frequency of small-scale somatic events in the tumor.
The diﬀerence between tumor and normal prostate varia-
tion frequencies shown in Figure 1A corresponds to 1.8
(±1.0) million somatic alterations per prostate tumor cell
genome. The relatively high standard deviation can
be attributed to the existence of both tumors with higher
(2.6±0.6million) and lower (1.0±0.36million) genomic
instability frequencies (Supplementary Figure S3), a
ﬁnding evident by the distribution of the variation fre-
quency per sample (Figure 1B). The absolute number of
variations and base pairs sequenced per sample is pre-
sented in Supplementary Table S1, along with the
sequence surrounding each variation.
Distinct etiologies may result in speciﬁc types of
variations in the tumor or in a speciﬁc DNA sequence
context. Thus, we decided to test these variations for the
presence of a speciﬁc motif we have previously found to be
overrepresented at the sites of tumor DNA mutations in
several genes (THEMIS motif; 11). We report that
variations in the tumor DNA occur in the context of the
THEMIS motif (with one mismatch allowed) signiﬁcantly
more often (78%) than in the normal prostate and blood
DNA (33%; two-sided P=0.046) (Figure 2A), suggesting
distinct molecular etiology in the tumors. In contrast,
the distribution of the variations by substitution type
did not vary signiﬁcantly between tumor and controls
(Figure 2B).
The methodology we utilized for estimating variation
frequencies was based on the premise that prostate
tumors may be genetically heterogeneous. Although the
results presented in Figure 1A suggest a signiﬁcant fre-
quency of genomic instability in prostate tumors, they
do not address the issue of cancer heterogeneity. In
order to probe the existence of heterogeneity in prostate
cancer, we employed the same methodology that we used
to measure variation frequencies, but with the addition of
a degenerate PCR step before cloning (see ‘Materials and
Methods’ section). This modiﬁcation resulted in the gen-
eration of multiple individual sequences from a small
number (10–15) of the same genomic regions for both
tumor and control DNA, after sequencing 60–100 clones
per sample. The ﬁrst prostate tumor sample we analyzed
showed extensive heterogeneity in one of those genomic
regions, speciﬁcally in the tumor (Figure 3). A diﬀerent
tumor sample showed a lower degree of heterogeneity
(two variations in each of three genomic regions, one of
these regions being the same region shown in Figure 3).
Thus, we conclude that there is signiﬁcant but variable
degree of genetic heterogeneity in prostate tumor
genomes. Likewise, prostate tumors show a variable
degree of genomic instability (Figure 1B).
Figure 1. Genomic variation rate is signiﬁcantly higher in prostate
tumors. Variation rates were calculated by our cloning/sequencing
protocol (see ‘Materials and Methods’ section). Variations found in
dbSNP build 129 were excluded. (A) Mean genomic variation rate.
Mean variation rate=mean number of variations/Kb sequenced. The
mean genomic variation rate is signiﬁcantly diﬀerent between prostate
tumor and the other two tissue types (normal prostate and blood;
P<0.05). (B) Individual genomic variation rate in six prostate cancer
patients. Variation rate=number of variations/Kb sequenced. Normal,
normal prostate; Tumor, prostate tumor. When not visible, the blood
rate is identical to the normal prostate rate, except for sample 1, for
which no blood was available.
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The average number of somatic events reported here in six
prostate cancers is orders of magnitude higher than
previous reports (4–9). Some of those studies analyzed
coding sequences (4–7), while others noncoding (8,9).
Thus, selection of coding region mutations during tumor
evolution cannot be responsible for this diﬀerence in vari-
ation frequencies. In contrast, either the tumor type
(prostate) or the PCR-free methodology we used may be
responsible for our ﬁnding. PCR-based analysis of various
tumors has revealed less extensive but signiﬁcant tumor-
to-tumor mutation and mutated ‘driver’ gene heterogene-
ity (4–7). Most of the mutations reported here are in
intergenic regions and thus presumably ‘passengers’ (i.e.
not tumor ‘drivers’; 16). If distinct cells of the same tumor
contain diﬀerent passengers, then they may also contain
diﬀerent drivers. This possibility can only be assessed by
single cell/molecule methods such as the one we employed
here. Before embarking on full-scale cancer genome
projects with techniques that may miss most mutations
in heterogeneous tumors it may be worthwhile ﬁrst to
use single cell/molecule approaches to classify tumors
based on their degree of heterogeneity. Then the appro-
priate method can be employed to the full project based
on tumor type (heterogeneous or not).
We report here an average tumor mutation frequency
that signiﬁcantly exceeds the current estimates (4–9). We
believe that this ﬁnding has important biological con-
sequences for prostate tumorigenesis. In addition to
ﬁnding signiﬁcantly higher mutation frequency in tumor
DNA, we observed that prostate tumors contain distinct
types of mutations: unlike normal prostate and blood
from the same patient, tumor mutations ﬁt the THEMIS
motif (11), suggesting a common etiology. We do not
know the exact molecular mechanism generating these
Figure 2. Distribution of the variations found by (A) the presence of the THEMIS motif and (B) substitution type. Variations found in dbSNP were
excluded. The data presented in (A) show the number of variations that occur (or not) in the context of the THEMIS motif with one mismatch
allowed. For a more compete explanation of the THEMIS motif, see text. Only the diﬀerences in (A) between the distribution of the variations in
the tumor and the other two types of tissue are signiﬁcant (P=0.046).
Figure 3. Genetic heterogeneity in prostate cancer. Data were obtained
using the same cloning/sequencing protocol utilized for measuring
genomic variation rates, with the inclusion of a degenerate PCR step
prior to cloning (see ‘Materials and Methods’ section). All clones
come from the same tumor sample. Numbers indicate clone number
(e.g. T2=tumor clone #2). The three clones grouped together in the
bottom contain wild-type sequence. Variations are capitalized and
shown in highlight. Only the minimum sequence needed to show the
maximum degree of heterogeneity is shown. These variations are not
present in dbSNP build 129.
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previous analysis of the THEMIS motif mutations in
several genes in prostate cancer tissue (11), this genomic
instability in prostate cancer may be the result of aberrant
DNA repair in the prostate.
In performing our genomic variation analysis, all of the
variations found from the best aligned match in Genbank
were scored, unless the number of variations represented
>5% of the total insert length, in which case the clone
sequence was rejected from the analysis (the level of
genetic diversity among diﬀerent normal individuals
rarely approaches 1% of the total sequence (17), so we
reasoned that more than 5-fold higher would be unlikely
even for the tumor DNA, and it probably represents a
sequencing artifact (either on our side or the Genbank
reference sequence). Using this criterion, ﬁve clones were
rejected from the analysis of the tumor DNA, six from
the normal prostate and seven from the blood DNA.
All but one of the rejected clones represented non-
unique sequence or included repeats (commonly
centromeric DNA). The best alignment for the remaining
clone is shown in Supplementary Figure 4, and may
represent template-independent DNA synthesis performed
by the tumor (18), or a fragment not yet sequenced by the
various human genome projects. We favor the former
explanation, since we were unable to PCR amplify this
clone speciﬁc fragment from all normal unrelated DNA
samples we examined (data not shown).
Variants in repeats are more likely to be uncharac-
terized polymorphisms (though not yet reported in
dbSNP) and thus may increase the total count for both
control and tumor DNAs. However, Supplementary
Figure S5 demonstrates that the excess of tumor
variations (especially substitutions) can not be merely
explained by repeat variations. Thus we decided to
include the repeat variants in our analysis. Subtracting
the repeat variations from the total count changes the fre-
quency estimate to 1.1 (±0.7) million somatic alterations
per prostate tumor cell genome.
The distribution of the variations by type
(Supplementary Figure S5) shows that unlike normal
prostate and blood, prostate tumors contain mostly
substitutions, not deletions or insersions. However, the
signiﬁcance of this ﬁnding is limited to small-scale tumor
alterations, because the utilization of a four base cutter
(AluI) in our cloning methodology does not allow us
to adequately examine large-scale genomic instability
(translocations, aneuploidy, etc.).
The genomic analysis reported here demonstrates that
normal prostate DNA does not show increased genomic
instability compared to blood (Figure 1A), suggesting that
ﬁxation artifacts (previously reported to artiﬁcially
increase mutation rates in formalin ﬁxed samples; 19) do
not play a major role in the data that we report here.
The utilization of a PCR-free approach may be responsi-
ble for this ﬁnding, since Taq DNA polymerase is thought
to be the cause of these artifacts (19). Most of the observed
variations in normal tissue (both prostate and blood)
are probably yet-unidentiﬁed polymorphisms. Some of
the tumor variations are also likely to be yet-unidentiﬁed
polymorphisms. This is a major reason we subtracted the
variation frequency of the normal from the tumor tissue,
in order to measure the somatic variation frequency
in tumors. Moreover, Figure 1B demonstrates that all
patients show an increase in the variation frequency spe-
ciﬁcally in the tumor genome (this trend is not signiﬁcant
for individual patients, probably due to the low number of
variations per patient).
In summary, a PCR-free methodology that measures
genomic variation rate reveals substantial somatic insta-
bility in prostate cancer. This ﬁnding suggests at least a
partial role for the mutator phenotype hypothesis (8) in
prostate tumor progression.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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